Æterna Zentaris to Present Data on Erk/PI3K Inhibitors at Upcoming AACR
Annual Meeting

QUÉBEC CITY, April 13 /CNW Telbec/ - Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.

    Abstract # 3856
      - Title: "A highly selective Erk-inhibitor with antiproliferative
        efficacy and the potential for combination therapy with modulators of
        the PI3K pathway", I. Seipelt, L. Blumenstein, S. Baasner, G.
        Mueller, B. Aicher, M. Teifel, E. Guenther, M. Gerlach.
        Oral Presentation: Session ID: Experimental and Molecular
        Therapeutics 29
        Tuesday, April 20, 2010, 10:30 AM - 1:00 PM

    Abstract # 4474
      - Title: "Dual inhibitors for PI3K and Erk induce growth inhibition of
        tumor cells", I. Seipelt, M. Gerlach, S. Baasner, L. Blumenstein, G.
        Mueller, B. Aicher, E. Guenther, M.l Teifel.
        Poster Presentation: Session ID: Experimental and Molecular
        Therapeutics 33
        Location: Exhibit Hall A-C, Poster Section 24
        Tuesday, April 20, 2010, 2:00 PM - 5:00 PM

Irene Seipelt, Ph.D., Associate Director, Drug Discovery & Preclinical Development at Æterna Zentaris, will make both presentations.

Copies of the abstracts are currently available and can be viewed on-line through the AACR 2010 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/abstracts.aspx.

About Æterna Zentaris Inc.

Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

SOURCE Aeterna Zentaris Inc.

For further information: For further information: Investor Relations: Ginette Vallières, Investor Relations Coordinator, (418) 652-8525 ext. 265, gvallieres@aezsinc.com; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, pburroughs@aezsinc.com

Organization Profile

Aeterna Zentaris Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890